Exploring the ability of the MD+FoldX method to predict SARS-CoV-2 antibody escape mutations using large-scale data.

Exploring the ability of the MD+FoldX method to predict SARS-CoV-2 antibody escape mutations using large-scale data.

Publication date: Oct 04, 2024

Antibody escape mutations pose a significant challenge to the effectiveness of vaccines and antibody-based therapies. The ability to predict these escape mutations with computer simulations would allow us to detect threats early and develop effective countermeasures, but a lack of large-scale experimental data has hampered the validation of these calculations. In this study, we evaluate the ability of the MD+FoldX molecular modeling method to predict escape mutations by leveraging a large deep mutational scanning dataset, focusing on the SARS-CoV-2 receptor binding domain. Our results show a positive correlation between predicted and experimental data, indicating that mutations with reduced predicted binding affinity correlate moderately with higher experimental escape fractions. We also demonstrate that higher precision can be achieved using affinity cutoffs tailored to distinct SARS-CoV-2 antibodies from four different classes rather than a one-size-fits-all approach. Further, we suggest that the quartile values of optimized cutoffs reported for each class in this study can serve as a valuable guide for future work on escape mutation predictions. We find that 70% of the systems surpass the 50% precision mark, and demonstrate success in identifying mutations present in significant variants of concern and variants of interest. Despite promising results for some systems, our study highlights the challenges in comparing predicted and experimental values. It also emphasizes the need for new binding affinity methods with improved accuracy that are fast enough to estimate hundreds to thousands of antibody-antigen binding affinities.

Open Access PDF

Concepts Keywords
Countermeasures Antibodies, Neutralizing
Molecular Antibodies, Neutralizing
Vaccines Antibodies, Viral
Valuable Antibodies, Viral
Antibody
COVID-19
DMS
Escape mutation
FoldX
Humans
MD
Molecular Dynamics Simulation
Mutation
Protein Binding
SARS-CoV-2
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2

Semantics

Type Source Name
drug DRUGBANK Spinosad
drug DRUGBANK Coenzyme M
drug DRUGBANK Succimer
disease MESH COVID 19
disease IDO host
disease MESH emergency
pathway REACTOME Immune System
disease IDO site
disease IDO protein
disease MESH point mutation
disease MESH Infection
drug DRUGBANK Amino acids
drug DRUGBANK Methionine
drug DRUGBANK Water
disease IDO production
disease IDO algorithm
disease MESH confusion
disease MESH mutation frequency
drug DRUGBANK Isoxaflutole
disease IDO process
drug DRUGBANK Lysozyme
disease MESH infectious diseases
drug DRUGBANK Mannose
drug DRUGBANK Glycine
drug DRUGBANK Trestolone
drug DRUGBANK Saquinavir
drug DRUGBANK Sulfasalazine
disease MESH viral infections
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Vorinostat
disease IDO infectivity
disease MESH influenza
disease MESH uncertainty
drug DRUGBANK Diethylstilbestrol
disease IDO blood
disease MESH cancer
drug DRUGBANK Isosorbide Mononitrate
pathway REACTOME Reproduction

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *